Welcome : Guest

Emphasis on Gynecological Health among Modern Women and Widespread Awareness Campaigns to Drive the Global Endometriosis Market


Published: January 2018

REPORT STATISTICS


  • Code: MCP-6433
  • Pages: 181
  • Tables: 33
  • Companies: 38


ENDOMETRIOSIS: A RESEARCH BRIEF

The global market for Endometriosis Drugs is projected to reach US$2.6 billion by 2022, driven by large-scale efforts towards awareness campaigns, and growing spending on treatment of gynecological disorders amid societal changes, worldwide. Growing awareness of the disease as the primary cause of infertility is helping result in increased diagnosis, early interventions, and improved prognosis. Better understanding and knowledge over the medical condition is also helping in the gradual dissipation of the stigma associated with the disease, leading to increased willingness to obtain medical help. All of these factors are expected to result in a drastic reduction in delayed diagnosis and benefit demand for endometriosis drugs. Future growth in the market will come from the launch of Neurocrine and Abbvies Elagolix, the first oral GnRH (gonadotropin releasing hormone) antagonist, superior to injectable GnRH agonists. The United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 3.4% over the analysis period, led by large population and unmet therapeutic needs for endometriosis, increasing awareness about the condition, and increasing healthcare spending among the growing base of affluent, middle class population. 

    Summary of Findings

  • Research Efforts Focused on Non-Hormonal Therapies for Endometriosis to Spearhead Future Growth in the Market
  • The Need for Long-Term Management of Endometriosis: The Cornerstone for Growth in the Endometriosis Drugs Market
  • Growing Research in the Pathophysiology of Endometriosis to Benefit the Development of Newer and More Potent Drugs
  • Close Association of Endometriosis with Infertility Throws the Emphasis on Early Diagnosis and Prevention of Disease Progression to Reduce Risk of Intractable Infertility

    Timeline for Analysis

  • Market Estimates and Forecasts for 2015-2022
  • Historic Review 2009-2014

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, and Rest of World

MAJOR PLAYERS

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Debiopharm Group
  • Evotec AG

KEY RESEARCH DELIVERABLES

  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable







Interested in our research, you can contact our 24/7 Research Support e-Desk at rsd@strategyr.com
or
info411@strategyr.com